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CLINICAL GUIDELINE FOR DIAGNOSIS AND MANAGEMENT OF MELIOIDOSIS
Timothy J.J. INGLIS(1), Dionne B. ROLIM(2) & Jorge L.N. RODRIGUEZ(3)
SUMMARY
Melioidosis is an emerging infection in Brazil and neighbouring South American countries. The wide range of clinical
presentations include severe community-acquired pneumonia, septicaemia, central nervous system infection and less severe soft
tissue infection. Diagnosis depends heavily on the clinical microbiology laboratory for culture. Burkholderia pseudomallei, the
bacterial cause of melioidosis, is easily cultured from blood, sputum and other clinical samples. However, B. pseudomallei can be
difficult to identify reliably, and can be confused with closely related bacteria, some of which may be dismissed as insignificant
culture contaminants. Serological tests can help to support a diagnosis of melioidosis, but by themselves do not provide a definitive
diagnosis. The use of a laboratory discovery pathway can help reduce the risk of missing atypical B. pseudomallei isolates.
Recommended antibiotic treatment for severe infection is either intravenous Ceftazidime or Meropenem for several weeks, followed
by up to 20 weeks oral treatment with a combination of trimethoprim-sulphamethoxazole and doxycycline. Consistent use of
diagnostic microbiology to confirm the diagnosis, and rigorous treatment of severe infection with the correct antibiotics in two
stages; acute and eradication, will contribute to a reduction in mortality from melioidosis.
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INTRODUCTION
Melioidosis is an emerging infectious disease in Brazil. This
potentially fatal bacterial infection is caused by exposure to soil or
water contaminated with the bacterial species Burkholderia
pseudomallei. The disease has been known in the Americas since the
middle of the 20th century when there was an outbreak in sheep, goats
and pigs in Aruba24. Since then sporadic cases of melioidosis have
occurred in Ecuador, Panama and possibly in Ceara1,19. The recent
cluster of melioidosis fatalities in rural Ceara has highlighted the
changing epidemiology of this disease. Survey data from Northeastern
Brazil indicates that melioidosis is a more important cause of
community-acquired sepsis than previously thought21.
A recurring issue where melioidosis is known but uncommon is
how best to confirm the diagnosis. In its most acute, life threatening
form the infection has no reliable pathognomonic features³¹. The
differential diagnosis is very wide. Baseline diagnostic tests offer little
help. The definitive diagnosis depends on culture of the causal bacterial
species, B. pseudomallei15 . But even when preliminary culture results
are returned from the microbiology laboratory, the result may not be
apparent because Gram negative septicaemia has many commoner
causes. The appearance of B. pseudomallei colonies on an agar plate
can be helpful after subculture from blood culture bottles onto solid
media, but only after 2-3 days of growth. Younger cultures may not
suggest B. pseudomallei so that the opportunity to make a definitive
early diagnosis may be missed. By this stage, usually 1-2 days after
collection of a blood or sputum culture, a severely sick patient may be
in respiratory distress or even dead. The methods used to identify Gram
negative bacteria in the microbiology laboratory can be very misleading.
Some do not reliably identify B. pseudomallei at all9. Physicians and
microbiologists need to know how to look for B. pseudomallei to
increase their chances of detecting it.
Antibiotic treatment of melioidosis also poses a challenge. Several
antibiotics commonly used for Gram negative septicaemia, including
Gentamicin, quinolones and third generation cephalosporins have no
reliable effect against B. pseudomallei infection¹³. The preferred
antibiotic treatment of B. pseudomallei septicaemia requires costly
intravenous agents3,27. There is a tendency for early relapse at around
10-14 days after commencement of intravenous antibiotic therapy².
Late relapse can occur months or even years after initial septicaemic
infection. An additional consequence of this capacity for melioidosis
to remain dormant is delayed presentation of acute infection many
decades after the initial exposure18.
In order to raise awareness of the clinical management issues, we
present our recommendations for diagnosis, treatment and continuing
care of melioidosis based on recent experience and best practice. These
guidelines will be subject to revision as diagnostic and therapeutic
2INGLIS, T.J.J.; ROLIM, D.B. & RODRIGUEZ, J.L.N. - Clinical guideline for diagnosis and management of melioidosis. Rev. Inst. Med. trop. S. Paulo, 48(1): 1-4, 2006.
systems improve to meet the challenges posed by this emerging
infection.
CASE DESCRIPTION
There are no reliable pathognomonic features of acute or subacute
melioidosis. Other infections including tuberculosis and typhoid fever
are commonly confused with melioidosis. The commonest clinical
presentation of the disease in northern Australia and Southeast Asia
where the infection appears to be commonest is septicaemia with or
without pneumonia (Table 1)4. Other focal organ involvement is
common either as a primary source of subsequent septicaemia or as a
due to localisation following bloodstream spread. Meningoencephalitis,
pneumonia without septicaemia, osteomyelitis, septic arthritis, spinal
involvement, localised abscesses in almost any deep organ or superficial
soft tissue have all been described. The majority of severe infections
occur in patients with a contributory co-morbidity such as uncontrolled
diabetes mellitus, chronic renal failure, alcoholic liver disease or
chronic lung disease17 . Overwhelming septicaemia does occasionally
occur in previously fit young adults. The subacute end of this disease
spectrum usually takes the form of localised superficial soft tissue
infection in patients with no associated co-morbidities15. Melioidosis
can present for the first time after a prolonged pre-patent period or
relapse after initially adequate antibiotic therapy followed by a
quiescent interval2,18. This capacity to develop into a subclinical form,
due to sequestration of dormant bacteria within the body was first
recognised in veterans of the Viet Nam conflict22. A history of soil or
surface water exposure and percutaneous inoculation may help identify
the patient at risk of melioidosis, but will be absent in a proportion of
subsequently diagnosed cases5.
DIAGNOSTIC INVESTIGATIONS
Confirmation of a diagnosis of melioidosis depends heavily on the
clinical microbiology laboratory, and specifically on recovering a B.
pseudomallei isolate by culture from blood, sputum, cerebrospinal fluid
or other bacteriology specimen15. The bacterial count in venous blood
(CFU/mL) can reach high levels during septicaemia and B. pseudomallei
grows easily so that conventional blood culture methods are an effective
means of establishing a bacteriological diagnosis28. Samples from non-
sterile sites are less helpful because the numbers of B. pseudomallei
may be much lower, and can be overwhelmed by larger numbers of
commensal species. This problem can be overcome by use of selective
agar to suppress commensal bacteria. The media used for this are
Ashdown’s Selective agar (ASA) or B. pseudomallei Selective Agar
(BPSA)7,29. ASA was developed for clinical bacteriology use, but may
inhibit the growth of some strains of B. pseudomallei, particularly those
that are excessively mucoid. BPSA was developed to improve recovery
of mucoid strains without reducing recovery of the classic wrinkled
type. A laboratory discovery pathway has been developed for B.
pseudomallei10. This comprises three stages (Table 2): an initial screen
of easily performed tests, confirmatory phenotypic methods and finally,
definitive genotypic confirmation. Substrate utilisation panels are used
in many laboratories to confirm the identity of suspected B.
pseudomallei6,16,25. These appear to perform well when there is an
expectation that the isolate is indeed B. pseudomallei, or when
evaluating a collection of isolates already identified by substrate
utilisation. However, neither the manual nor the automated substrate
utilisation panels used to identify unknown Gram negative bacilli from
Table 1
Clinical presentations of melioidosis
Commonest acute presentations
Pneumonia
Pneumonia with septicaemia
Septicaemia
Other presentations
Soft tissue infection: cellulitis, fasciitis, skin abscess/ulcer
Bone and joint infection: osteomyelitis, septic arthritis
Genitourinary: prostatic abscess
CNS infection: cerebral abscess, meningoencephalitis,
encephalomyelitis
Facial: suppurative parotitis
Ocular infection: conjunctival ulcer, hypopyon, orbital cellulitis
Incidental finding
asymptomatic seroconversion
Table 2
Laboratory criteria for confirmation of B. pseudomallei infection
Definitive:
culture of a Gram negative bacillus from blood, other sterile fluid or
sputum sample with the following features
ALL of ..
Oxidase positive
Gentamicin resistant
Polymyxin (Colistin) resistant
PLUS one or more of ..
B. pseudomallei agglutinating antibody positive
B. pseudomallei-specific PCR positive
B. pseudomallei 16s DNA sequence positive
Supportive, but not definitive:
Gram negative bacillus from blood, other sterile fluid or sputum
sample without any positive confirmatory tests in a clinical
setting consistent with melioidosis
Gram negative bacillus from blood, other sterile fluid or sputum
sample in a clinical setting consistent with melioidosis, with
positive first line tests (oxidase +, GM/POLY R) a
contradictory bacterial identification panel (e.g. API, Vitek
etc) but awaiting definitive test
A fourfold or greater rise in B. pseudomallei antibodies by IHA
or ELISA in a clinical setting consistent with melioidosis
A single very high B. pseudomallei antibody titre in a clinical
setting consistent with melioidosis
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blood cultures are fully reliable9,14. Where molecular tests are not
available, substrate utilisation panels should be used with caution after
taking into account the results of simple preliminary tests such as Gram
stain, oxidase and antibiotic susceptibility pattern6,10. Alternatively, they
can be used to supplement other identification tests, or they may be
used in reference laboratories as part of classical bacteriological
identification procedures that rely on polyphasic determinative
bacteriological methods10. All suspected B. pseudomallei isolates should
be stored on agar slopes or in glycerol broth at -70 oC for future reference
laboratory work, even when preliminary results suggest that the isolate
in question is another bacterial species. We still encounter occasional
referred clinical isolates that have been identified as another bacterial
species and that subsequently prove to be B. pseudomallei. Moreover,
our current discovery pathway will probably require amendment when
the more recent PCR protocols have been evaluated. Isolates referred
for definitive identification and molecular typing should be transferred
to reference laboratories in accordance with current UN/IATA
guidelines. International transfers must also comply with the respective
national quarantine regulations.
Serological evidence of infection can be obtained by indirect
haemagglutination assay (IHA)30, but seroconversion is unlikely to
occur early enough to affect treatment choices during the admission
phase of a severe, acute infection. False negatives do occur and though
ELISA-based or indirect immunofluorescent (IFAT) tests have improved
the sensitivity and specificity in some centres, they have not completely
resolved this problem26. Seroconversion or a single high IHA titre (e.g.
> 160) in the absence of a positive culture is therefore regarded as
supportive rather than definitive evidence of melioidosis15. The level
of titre regarded as diagnostic will vary in different locations according
to local melioidosis epidemiology.
IMMEDIATE AND CONTINUATION THERAPY
Clinical trials have shown a significant reduction in mortality by
early intervention with a suitable intravenous antibiotic, and comparable
results with other, newer agents. Ceftazidime was the first antibiotic
to produce clear improvements in mortality (Table 3)27. There are
theoretic reasons why a carbapenem should be used instead for severe
infections11, and both Imipenem and Meropenem have been shown to
be at least as good as Ceftazidime3,23. Supplementary antibiotic agents
may have a place in treating persistent bacteraemic infection, or
reducing the risk of early relapse but it is not yet clear which agent is
most suitable or when it should be introduced. Other measures that
may also be important for specific patients with severe, acute infection
include correction of metabolic acidosis, ketosis, diabetic control and
oxygenation¹². All these factors are likely to assist phagocytic function
and possibly reduce the risk of late relapse. There is a lack of consensus
on exactly how long to continue intravenous antibiotics and what to
continue for oral eradication therapy. These issues will only be resolved
by carefully planned clinical trials.
CONCLUSION
Melioidosis presents a diagnostic challenge to both the physician
and the diagnostic laboratory scientist. The poor sensitivity and speed
of current methods of laboratory diagnosis of melioidosis will continue
to frustrate the primary diagnostician for some time to come. The 2003
melioidosis case cluster in Ceara, in which three of the four presumed
cases succumbed to infection, illustrated these problems20,21. No
bacteriological diagnosis was possible in the first case. The Gram negative
bacillus from blood culture in the second case didn’t survive long enough
for definitive identification by the state public health laboratory, and the
one surviving case had no positive culture but a delayed seroconversion
by IHA. A definitive, culture-based diagnosis was only made in the third
case after several days of processing an unfamiliar Gram negative isolate
whose initial appearance resembled Yersinia pestis on the Gram stain.
This result came too late to prevent a fatal outcome, but did alter the
choice of antibiotic therapy for the one survivor. We believe that increased
awareness of the varied clinical presentation of melioidosis and correct
choice of diagnostic methods will result in faster diagnosis and a better
prognosis for those with acute, septicaemic disease. This must be matched
by enhanced clinical laboratory capability, including the development
of a melioidosis reference laboratory. The capacity to deliver melioidosis
reference tests is under development in Ceara, where the majority of
recent cases have presented. Finally, effective antibiotic therapy is
available for this potentially fatal infection. Use of the recommended
regimes will reduce the mortality from this disease and help prevent its
subsequent relapse.
RESUMO
Recomendações clínicas para o diagnóstico e
tratamento da melioidose
Melioidose é uma infecção emergente no Brasil e em países
vizinhos da América do Sul. O amplo espectro de apresentação clínica
Table 3
Antibiotic therapy for culture confirmed melioidosis
Severe, acute melioidosis including septicaemia, with or without
pneumonia, central nervous system infection and other invasive
forms of the disease:
EITHER
Ceftazidime (adult)
2-3 g or 40 mg/kg/dose every eight hours intravenously for 2-4
weeks
PLUS
Co-trimoxazole (Trimethoprim-Sulphamethoxazole)
10/50 mg/kg (up to 320/1600 g) every 12 hours
OR
Meropenem
1 g or 25 mg/kg every eight hours intravenously for ≥ 2 weeks
Eradication phase
1 Trimethoprim-Sulphamethoxazole 8/40 mg/kg every 12 hours for
≥ 12-20 weeks
2 Doxycycline 4 mg/kg/day plus Trimethoprim-Sulphamethoxazole
8/40 mg/kg every 12 hours for ≥ 12-20 weeks
3 Chloramphenicol 40 mg/kg/day plus Doxycycline 4 mg/kg/day,
Trimethoprim-Sulphamethoxazole 8/40 mg/kg every 12 hours for
≥ 12-20 weeks
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inclui pneumonia adquirida na comunidade, septicemia, infecção do
sistema nervoso central e infecção de partes moles de menor severidade.
O diagnóstico depende essencialmente da identificação microbiológica.
Burkholderia pseudomallei, a causa bacteriana da melioidose, é
facilmente cultivada em sangue, escarro e em outras amostras clínicas.
Entretanto, B. pseudomallei pode ser difícil de identificar com segurança
e também ser confundido com outras bactérias Gram negativas. Os
exames sorológicos podem dar suporte a um diagnóstico de melioidose,
mas não fornece um diagnóstico definitivo por si só. A realização de
investigação laboratorial seqüenciada pode ajudar a reduzir o risco de
não reconhecer isolados incomuns de B. pseudomallei. O tratamento
antibiótico recomendado para infecção severa é Ceftazidima ou
Meropenem endovenosos por várias semanas, seguido por um
tratamento oral com uma combinação de Sulfametoxazol-Trimetopim
e Doxiciclina por até 20 semanas. O uso consistente do diagnóstico
microbiológico e o tratamento rigoroso da infecção severa com
antibióticos adequados nas duas etapas, aguda e de erradicação,
contribuirão para a redução da mortalidade por melioidose.
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